Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05050084 · ClinicalTrials.gov registry record · Phase 3
Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial
A Phase 3 study of Prostate Adenocarcinoma, sponsored by NRG Oncology.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 2,050
- Enrollment target
- 20
- Study locations
NCT05050084 is a Phase 3 study of Prostate Adenocarcinoma that is actively recruiting participants, run by NRG Oncology. The registered enrollment target is 2,050 participants, above the 198-participant average among 99 other Prostate Adenocarcinoma trials with a reported enrollment target (935% higher). The trial reports 20 study locations across 4 states.
The verdict
NCT05050084, a Phase 3 study of Prostate Adenocarcinoma, is actively recruiting participants, sponsored by NRG Oncology.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 2,050 participants
- Enrollment target
- 20
- Study locations
Study Summary
This phase III trial uses the Decipher risk score to guide therapy selection. Decipher score is based on the activity of 22 genes in prostate tumor and may predict how likely it is for recurrent prostate cancer to spread (metastasize) to other parts of the body. Decipher score in this study is used for patient selection and the two variations of treatment to be studied: intensification for higher Decipher score or de-intensification for low Decipher score. Patients with higher Decipher risk score will be assigned to the part of the study that compares the use of 6 months of the usual treatment (hormone therapy and radiation treatment) to the use of darolutamide plus the usual treatment (intensification). The purpose of this section of the study is to determine whether the additional drug can reduce the chance of cancer coming back and spreading in patients with higher Decipher score. The addition of darolutamide to the usual treatment may better control the cancer and prevent it from spreading. Alternatively, patients with low Decipher risk score will be assigned to the part of the study that compares the use of radiation treatment alone (de-intensification) to the usual approach (6 months of hormone therapy plus radiation). The purpose of this part of the study is to determine if radiation treatment alone is as effective compared to the usual treatment without affecting the chance of tumor coming back in patients with low Decipher score prostate cancer. Radiation therapy uses high energy to kill tumor cells and reduce the tumor size. Hormone therapy drugs such as darolutamide suppress or block the production or action of male hormones that play role in prostate cancer development. Effect of radiation treatment alone in patients with low Decipher score prostate cancer could be the same as the usual approach in stabilizing prostate cancer and preventing it from spreading, while avoiding the side effects associated with hormonal therapy.
Conditions Studied
Interventions
- DRUG Darolutamide
- DRUG Bicalutamide
- DRUG Degarelix
- DRUG Buserelin
- DRUG Flutamide
Study Locations (20)
California
- Sutter Cancer Centers Radiation Oncology Services-Auburn - Auburn
- AIS Cancer Center at San Joaquin Community Hospital - Bakersfield
- Tower Cancer Research Foundation - Beverly Hills
- Sutter Cancer Centers Radiation Oncology Services-Cameron Park - Cameron Park
- City of Hope Corona - Corona
- City of Hope Comprehensive Cancer Center - Duarte
- Kaiser Permanente Dublin - Dublin
- UC San Diego Health System - Encinitas - Encinitas
- Kaiser Permanente-Fremont - Fremont
- Washington Hospital - Fremont
- Kaiser Permanente Fresno Orchard Plaza - Fresno
- Kaiser Permanente-Fresno - Fresno
Arizona
- Banner MD Anderson Cancer Center - Gilbert
- Arizona Center for Cancer Care - Gilbert - Gilbert
- Arizona Center for Cancer Care-Peoria - Peoria
- Arizona Center for Cancer Care - Phoenix - Phoenix
- Arizona Center for Cancer Care - Scottsdale - Scottsdale
- Arizona Center for Cancer Care-Surprise - Surprise
Alabama
- University of Alabama at Birmingham Cancer Center - Birmingham
Arkansas
- University of Arkansas for Medical Sciences - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,050 participants |
| Start Date | 2021-12-06 |
| Est. Completion | 2026-11-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05050084
The ClinicalTrials.gov registry entry for NCT05050084 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 2,050 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 198-participant average among 99 other Prostate Adenocarcinoma trials with a reported enrollment target (935% higher). The listed sponsor is NRG Oncology, which has 64 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Prostate Adenocarcinoma appearing as the primary indexed condition, and to 5 interventions - of which Darolutamide is the first listed.
NCT05050084 reports 20 study locations spanning 4 distinct geographic areas - top geographies include California, Arizona, Alabama.
Frequently Asked Questions
What is clinical trial NCT05050084 about?
NCT05050084 is a clinical study titled "Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial". This phase III trial uses the Decipher risk score to guide therapy selection. Decipher score is based on the activity of 22 genes in prostate tumor and may predict how likely it is for recurrent prostate cancer to spread (metastasize) to other parts of the body. Decipher score in this study is used ...
What is the current status of trial NCT05050084?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 2,050 participants. The study started on 2021-12-06. Estimated completion is 2026-11-11.
What conditions does trial NCT05050084 study?
This clinical trial studies the following conditions: Prostate Adenocarcinoma.
What interventions are being tested in trial NCT05050084?
The interventions under investigation include: Darolutamide (DRUG), Bicalutamide (DRUG), Degarelix (DRUG), Buserelin (DRUG), Flutamide (DRUG).
Who is sponsoring clinical trial NCT05050084?
This trial is sponsored by NRG Oncology, which has 64 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05050084 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer
RECRUITING · Phase 3
-
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
RECRUITING · Phase 3
-
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
RECRUITING · Phase 3
-
Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE Trial
RECRUITING · Phase 3
-
Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial
ACTIVE NOT RECRUITING · Phase 3
-
Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.